Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMABNASDAQ:OPTNNASDAQ:THRXNYSE:ZVIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMABI-Mab$2.33-3.9%$1.53$0.60▼$3.08$189.86M1.17432,646 shs416,555 shsOPTNOptiNose$9.60$9.52$4.82▼$19.50$97.22M-0.8862,481 shsN/ATHRXTheseus Pharmaceuticals$4.06$4.06$2.05▼$12.37$179.57M3.98592,167 shsN/AZVIAZevia PBC$3.08-4.5%$2.76$0.62▼$4.99$228.97M0.85533,106 shs470,563 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMABI-Mab-5.84%-1.63%+86.15%+207.18%+44.91%OPTNOptiNose0.00%0.00%0.00%+4.92%-38.46%THRXTheseus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ZVIAZevia PBC-10.74%-0.61%+19.12%+47.61%+379.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMABI-Mab3.1276 of 5 stars3.73.00.00.03.21.70.6OPTNOptiNose0.6937 of 5 stars1.00.00.04.20.61.70.6THRXTheseus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AZVIAZevia PBC0.5184 of 5 stars1.03.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMABI-Mab 3.33Buy$6.00158.06% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideTHRXTheseus Pharmaceuticals 0.00N/AN/AN/AZVIAZevia PBC 2.00Hold$3.389.76% UpsideCurrent Analyst Ratings BreakdownLatest ZVIA, IMAB, OPTN, and THRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.005/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/5/2025ZVIAZevia PBCTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$3.00 ➝ $3.004/4/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMABI-Mab$3.89M48.81N/AN/A$2.47 per share0.94OPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83THRXTheseus PharmaceuticalsN/AN/AN/AN/A$5.36 per shareN/AZVIAZevia PBC$155.05M1.47N/AN/A$0.59 per share5.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)THRXTheseus Pharmaceuticals-$50.61M-$1.34N/AN/AN/AN/A-24.84%-23.64%N/AZVIAZevia PBC-$20M-$0.31N/AN/AN/A-12.58%-35.52%-23.13%8/6/2025 (Estimated)Latest ZVIA, IMAB, OPTN, and THRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million5/7/2025Q1 2025ZVIAZevia PBC-$0.10-$0.06+$0.04-$0.08$37.15 million$38.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMABI-MabN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ATHRXTheseus PharmaceuticalsN/AN/AN/AN/AN/AZVIAZevia PBCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMABI-MabN/A22.3522.35OPTNOptiNoseN/A0.790.72THRXTheseus PharmaceuticalsN/A29.9329.93ZVIAZevia PBCN/A2.341.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMABI-Mab38.38%OPTNOptiNose85.60%THRXTheseus Pharmaceuticals91.05%ZVIAZevia PBC53.21%Insider OwnershipCompanyInsider OwnershipIMABI-Mab22.10%OPTNOptiNose2.30%THRXTheseus Pharmaceuticals46.70%ZVIAZevia PBC12.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMABI-Mab38081.66 million63.61 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableTHRXTheseus Pharmaceuticals3844.23 million23.58 millionOptionableZVIAZevia PBC13074.22 million64.91 millionOptionableZVIA, IMAB, OPTN, and THRX HeadlinesRecent News About These CompaniesZVIA - Zevia PBC Class A Ownership - Morningstar4 hours ago | morningstar.comMZevia: Higher Valuation Provides A Weak Risk-To-Reward (Rating Downgrade)June 19, 2025 | seekingalpha.com5 Soft Drink Stocks to Watch as Health Trends Shake Up the IndustryJune 9, 2025 | zacks.comShort Interest in Zevia PBC (NYSE:ZVIA) Decreases By 13.2%June 5, 2025 | marketbeat.comConsumer Sentiment Hits New Low: 3 Consumer Staple Stocks to BuyMay 23, 2025 | zacks.comAnalysts Conflicted on These Consumer Goods Names: Coca Cola Femsa SAB De CV (KOF), Sprouts Farmers (SFM) and Zevia PBC (ZVIA)May 16, 2025 | theglobeandmail.comZevia PBC (NYSE:ZVIA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comCautious Optimism for Zevia PBC Amid Promising Developments and Market ChallengesMay 12, 2025 | tipranks.comZevia PBC (ZVIA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comEarnings call transcript: Zevia’s Q1 2025 sees improved margins, reduced lossesMay 9, 2025 | investing.comQ1 2025 Zevia PBC Earnings CallMay 8, 2025 | uk.finance.yahoo.comZevia PBC (ZVIA) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic Expansion ...May 8, 2025 | finance.yahoo.comCautious Outlook on Zevia PBC: Hold Rating Amid Growth UncertaintiesMay 8, 2025 | tipranks.comZevia (ZVIA) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comZevia Announces First Quarter 2025 ResultsMay 7, 2025 | businesswire.comZevia Announces May Conference ParticipationApril 30, 2025 | finance.yahoo.comZevia to Announce First Quarter 2025 Earnings Results on May 7, 2025April 23, 2025 | businesswire.comCoca-Cola Is the King of the Mountain, But These 8 Beverage Companies Are Gaining SteamApril 20, 2025 | 247wallst.comZevia: Distribution Gains Are Needed For ProfitabilityMarch 18, 2025 | seekingalpha.comZevia PBC (ZVIA): the Best Vegan Stock to Buy According to AnalystsMarch 7, 2025 | insidermonkey.comZevia price target raised to $2.75 from 95c at Morgan StanleyMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVIA, IMAB, OPTN, and THRX Company DescriptionsI-Mab NASDAQ:IMAB$2.33 -0.10 (-3.93%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.OptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Theseus Pharmaceuticals NASDAQ:THRXTheseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.Zevia PBC NYSE:ZVIA$3.08 -0.15 (-4.50%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated beverages in the United States and Canada. It offers soda, energy drinks, organic tea, and kidz drinks. The company offers its products through a network of food, drug, warehouse club, mass, natural, convenience, and e-commerce channels, as well as grocery distributors and natural product stores and specialty outlets. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
